Foreign Investment & Trade
Notable Representations, Key Contacts
Our team works collaboratively with the M&A and Private Equity teams on the structuring and negotiation of transactions in an effort to anticipate and address regulatory concerns in the earliest stages of transaction planning. Given our broad-based experience, we are able to help clients proactively identify, understand and resolve CFIUS issues, often during strategic corporate development planning. Our experience across business sectors helps our clients address potential national security concerns well before any engagement with CFIUS occurs.
Our FIT team also provides comprehensive strategic counseling related to a wide variety of international trade matters, including: transactional due diligence and compliance with sanctions administered by the Office of Foreign Assets Control (OFAC); export controls administered by the Bureau of Industry and Security (BIS) and Directorate of Defense Trade Controls (DDTC); import/customs; the Foreign Corrupt Practices Act (FCPA); and other anti-bribery and anti-corruption laws, anti-money laundering laws, anti-boycott laws and other international trade and investment matters.
The FIT team has deep experience in numerous industry sectors, including technology, telecommunications, energy, real estate, financial services, health care and pharma, manufacturing, transportation, infrastructure and consumer goods.
Key Contacts
See list of lawyers globally
Shortcut Links
Awards and Recognition, Speaking Engagements, Latest Thinking, Firm News & Announcements
Awards and Recognition
- Weil Named a “Leading” Firm for CFIUS in the US Award Brief — IFLR1000 2024
- Shawn Cooley Named a “Leading” Lawyer for International Trade: CFIUS Experts Award Brief — Chambers Global 2024
- Weil Named a “Leading” Firm for International Trade Award Brief — Legal 500 US 2022
Speaking Engagements
-
9th National Conference on CFIUS
Speaker(s):
Shawn B. Cooley
April 13, 2023 — Washington, D.C. — Weil Corporate partner Shawn B. Cooley spoke on a panel titled “Non-Notified Transactions: Unpacking How the Committee is Now Approaching Reviews and Approvals – and the Timelines” as part of American Conference Institute’s 10th National Conference on CFIUS.
Latest Thinking
- CFIUS Bears Its Teeth While Demonstrating Further Sophistication: 2023 Annual Report Shows Increased Enforcement and More Efficiency Alert — Foreign Investment & Trade — By Shawn B. Cooley, Nathan Cunningham and Christina Carone — PDF — August 12, 2024
- CFIUS Publishes Two New FAQs that have Material Implications for Parties Filing with CFIUS Alert — Foreign Investment & Trade — By Shawn B. Cooley, Nathan Cunningham and Christina Carone — PDF — June 05, 2023
- CFIUS Seeks to Expand its Jurisdiction Over Real Estate Transactions via Proposed New Rule Alert — Foreign Investment & Trade — By Shawn B. Cooley, Nathan Cunningham and Christina Carone — PDF — May 15, 2023
- From the Bully Pulpit: President Biden Orders CFIUS to Strengthen Its Reviews in Light of Evolving National Security Risks Alert — Foreign Investment & Trade — By Shawn B. Cooley, Nathan Cunningham, Timothy C. Welch and Christina Carone — PDF — October 03, 2022
Firm News & Announcements
- Weil Advised Halozyme Therapeutics, Inc. in its $960M Acquisition of Antares Pharma, Inc. Deal Brief — May 24, 2022
- Weil Advised Blackstone in its Sale of Concert Golf Partners to Clearlake Capital Group Deal Brief — April 21, 2022
- Weil Advised CVC Capital Partners in its Acquisition of Radwell International, LLC Deal Brief — April 01, 2022
- Weil Advised Cornell Capital-Backed kdc/one in Investment by KKR and Acquisition of Aerofil Technology, Inc. Deal Brief — March 30, 2022
- Weil Advised Allego Holding B.V. in its $3.14B Business Combination with Spartan Acquisition Corp. III Deal Brief — March 16, 2022
- Weil Advised Sanofi in its up to $1.225B Acquisition of Amunix Pharmaceuticals, Inc. Deal Brief — February 08, 2022
- Weil Advised Gores Metropoulos II, Inc. in its $1.925B Business Combination with Sonder Holdings Inc. Deal Brief — January 18, 2022
- Weil Advised Magellan Health in its $2.2B Merger with Centene Corporation Deal Brief — January 06, 2022